key: cord-0253370-hh0laklx
authors: Zheng, H.; Cao, Y.; Chen, X.; Wang, F.; Hu, Y.; Song, W.; Chai, Y.; Gu, Q.; Shi, Y.; Feng, Y.; Liu, S.; Xie, Y.; Xie, X. S.; Jiang, W.; Shen, Z.
title: Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study
date: 2022-04-16
journal: nan
DOI: 10.1101/2022.04.09.22273653
sha: cab00048abe92fa561f4f005be3c2ffdfe72c3f3
doc_id: 253370
cord_uid: hh0laklx

Background SARS-CoV-2 Omicron variant BA.1 first emerged on the Chinese mainland in January 2022 in Tianjin and caused a large wave of infections. During mass PCR testing, a total of 430 cases infected with Omicron were recorded between January 8 and February 7, 2022, with no new infections detected for the following 16 days. Most patients had been vaccinated with SARS-CoV-2 inactivated vaccines. The disease profile associated with BA.1 infection, especially after vaccination with inactivated vaccines, is unclear. Whether BA.1 breakthrough infection after receiving inactivated vaccine could create a strong enough humoral immunity barrier against Omicron is not yet investigated. Methods We collected the clinical information and vaccination history of the 430 COVID-19 patients infected with Omicron BA.1. Re-positive cases and inflammation markers were monitored during the patient's convalescence phase. Ordered multiclass logistic regression model was used to identify risk factors for COVID-19 disease severity. Authentic virus neutralization assays against SARS-CoV-2 wildtype, Beta and Omicron BA.1 were conducted to examine the plasma neutralizing titers induced after post-vaccination Omicron BA.1 infection, and were compared to a group of uninfected healthy individuals who were selected to have a matched vaccination profile. Findings Among the 430 patients, 316 (73.5%) were adults with a median age of 47 years, and 114 (26.5%) were under-age with a median age of 10 years. Female and male patients account for 55.6% and 44.4%, respectively. Most of the patients presented with mild (47.7%) to moderate diseases (50.2%), with only 2 severe cases (0.5%) and 7 (1.6%) asymptomatic infections. No death was recorded. 341 (79.3%) of the 430 patients received inactivated vaccines (54.3% BBIBP-CorV vs. 45.5% CoronaVac), 49 (11.4%) received adenovirus-vectored vaccines (Ad5-nCoV), 2 (0.5%) received recombinant protein subunit vaccines (ZF2001), and 38 (8.8%) received no vaccination. No vaccination is associated with a substantially higher ICU admission rate among Omicron BA.1 infected patients (2.0% for vaccinated patients vs. 23.7% for unvaccinated patients, P<0.001). Compared with adults, child patients presented with less severe illness (82.5% mild cases for children vs. 35.1% for adults, P<0.001), no ICU admission, fewer comorbidities (3.5% vs. 53.2%, P<0.001), and less chance of turning re-positive on nucleic acid tests (12.3% vs. 22.5%, P=0.019). For adult patients, compared with no prior vaccination, receiving 3 doses of inactivated vaccine was associated with significantly lower risk of severe disease (OR 0.227 [0.065-0.787], P=0.020), less ICU admission (OR 0.023 [0.002-0.214], P=0.001), lower re-positive rate on PCR (OR 0.240 [0.098-0.587], P=0.002), and shorter duration of hospitalization and recovery (OR 0.233 [0.091-0.596], P=0.002). At the beginning of the convalescence phase, patients who had received 3 doses of inactivated vaccine had substantially lower systemic immune-inflammation index (SII) and C-reactive protein than unvaccinated patients, while CD4+/CD8+ ratio, activated Treg cells and Th1/Th2 ratio were higher compared to their 2-dose counterparts, suggesting that receipt of 3 doses of inactivated vaccine could step up inflammation resolution after infection. Plasma neutralization titers against Omicron, Beta, and wildtype significantly increased after breakthrough infection with Omicron. Moderate symptoms were associated with higher plasma neutralization titers than mild symptoms. However, vaccination profiles prior to infection, whether 2 doses versus 3 doses or types of vaccines, had no significant effect on post-infection neutralization titer. Among recipients of 3 doses of CoronaVac, infection with Omicron BA.1 largely increased neutralization titers against Omicron BA.1 (8.7x), Beta (4.5x), and wildtype (2.2x), compared with uninfected healthy individuals who have a matched vaccination profile. Interpretation Receipt of 3-dose inactivated vaccines can substantially reduce the disease severity of Omicron BA.1 infection, with most vaccinated patients presenting with mild to moderate illness. Child patients present with less severe disease than adult patients after infection. Omicron BA.1 convalescents who had received inactivated vaccines showed significantly increased plasma neutralizing antibody titers against Omicron BA.1, Beta, and wildtype SARS-CoV-2 compared with vaccinated healthy individuals.

Notably, the participants in many of these studies have received only one or two doses of inactivated vaccine with heterologous booster vaccination; other studies have a limited number of participants receiving inactivated vaccines.

To date, this is the first study to report on the protective effect of inactivated vaccines against the severe disease caused by the Omicron variant. We examine and compare the disease profile of adults and children. Furthermore, we estimate the effect of post-vaccination omicron infection on plasma neutralization titers against Omicron and other SARS-COV-2 variants.

Specifically, the disease profile of Omicron convalescents who had received two-dose primary series of inactivated vaccines with or without a booster dose prior to infection is compared with unvaccinated patients. We also analyzed the effect of infection on neutralizing activity by comparing vaccinated convalescents with vaccinated healthy individuals with matched vaccination profiles.

Coronavirus disease 2019 (COVID- 19) , an acute respiratory infectious disease caused by SARS-CoV-2, hit the world by surprise over two years ago and still is wreaking havoc worldwide. Multiple variants of concern (VOCs) have emerged with varied transmissibility and immune evasiveness, capable of causing breakthrough infections in vaccinated individuals and those with prior infection. Currently, the highly mutated Omicron is the dominant variant circulating in multiple countries and regions, and is still on the rise, 1 

This study analyzed clinical and demographic data on the 430 Omicron patients reported by Tianjin Municipal Health Commission between January 8 and February 7, 2022, including COVID-19 vaccination history, laboratory tests, clinical symptoms, ICU admission and death.

These data were extracted from the medical records obtained from Tianjin Haihe Hospital and Tianjin First Central Hospital where the patients received treatment after diagnosis.

In this study, laboratory diagnosis was done in two designated COVID-19 hospitals: Tianjin Haihe Hospital and Tianjin First Central Hospital. Nucleic acid was extracted from respiratory samples using commercial kits (Zybio, 5203050). Reverse Transcription-Polymerase Chain Reaction (RT-PCR) was performed following the WHO protocol to detect two target genes, the open reading frame of 1ab (ORF1ab) and the nucleocapsid protein (N). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.09.22273653 doi: medRxiv preprint (50°C for 10 min, 90°C for 5 min, 95°C for 10 s; 55°C for 40 s) were performed. A cycle threshold value (Ct-value) less than 37 with an S-shape amplification curve was defined as positive, and a Ct-value no less than 40 without a S-shape amplification curve was defined as negative. In the case of 37 ≤ Ct < 40, retesting would be recommended. If both target genes (ORF1ab and N) are tested positive on real-time RT-PCR for the same sample, the result would be regarded as positive; if only one of the two target genes is tested positive, resampling and retesting would be required. If one of the two target genes is tested positive for two samples, the result would be positive.

Peripheral blood was collected from 140 Omicron BA.1 convalescent patients 28 days after discharge and 114 healthy recipients of 3 doses of inactivated vaccines (CoronaVac) around 90 days after the booster shot. Whole blood samples were then diluted with PBS+2%FBS at 1:1 for Ficoll gradient centrifugation (Cytiva, 17-1440-03). Plasma was collected from the supernatants and restored at -80℃.

A neutralization assay of authentic SARS-CoV-2 was performed using a cytopathic effect (CPE) assay. Briefly, various concentrations (2-fold serial dilution using DMEM) of plasma were mixed with the same volume of 100 PFU of authentic SARS-CoV-2 and incubated at 37°C for 1 h. The mixture was added to a monolayer of Vero-E6 cells (5x10 3 cells per well) in a 96-well plate and incubated for 1 h at 37°C. The supernatant was removed, and 200 μL of DMEM supplied with 2% (v/v) FBS was added to the infected cells. After incubation at 37°C supplied with 5% CO2 for 5 days, all wells were examined for the CPE effect. All experiments were performed in a Biosafety Level 3 facility. Neutralization titers were calculated by the Spearman-Karber method.

The primary endpoints were COVID-19 severity and neutralizing antibody titers. COVID-19 disease severity was defined as asymptomatic, mild, moderate, severe and critical according to WHO living guidance for clinical management of COVID-19. 6 Secondary endpoints were intensive care unit (ICU) admission, re-positive results on nucleic acid tests, and duration of hospitalization and recovery. PCR re-positive was defined as PCR Ct value < 40 after two independent PCR-negative results at an interval of more than 24 hours.

Hospital and Tianjin First Central Hospital, respectively. All patients, including asymptomatic and mild cases, were hospitalized in Tianjin Haihe Hospital upon positive PCR results. Patients . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.09.22273653 doi: medRxiv preprint were discharged from Tianjin Haihe Hospital if the following criteria were met: 1) body temperature restored and stayed normal for over 3 days; 2) respiratory symptoms significantly relieved; 3) acute exudation substantially resolved on imaging study of the lungs; 4) negative on two consecutive PCR tests (at an interval of at least 24 hours) of samples collected from the respiratory tract. For patients whose PCR assays remained positive for over 4 weeks after criteria 1), 2) and 3) had been met, antibody assay and virus culture were applied to assess the risk of transmission before deciding whether these patients could be discharged. 

This study was approved by the Tianjin Municipal Health Commission and the Ethics Committee of Tianjin First Central Hospital (Ethics committee archiving No. 2022N045KY).

All patients/participants provided their written informed consent to have their clinical information collected for study purposes and the data generated from the study published. All the authors contributed to data collection and analysis, discussion and interpretation of the results. All the authors read and approved the final manuscript.

Continuous variables were shown in medians and interquartile ranges (IQR), and the Mann-Whitney U test was used to analyze the differences between the two groups. Categorical variables were summarized as counts and percentages, and analyzed by Pearson's χ2 test.

Ordered multi-class Logistic regression model was used to analyze the relations between age/gender/receipt of inactivated vaccine and COVID-19 severity. All the analyses were conducted using the SPSS software, version 22.0. Two-sided P<0.05 was used in tests of significance.

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ;

During citywide mass testing, a total of 430 cases infected with Omicron BA.1 were recorded between January 8 and February 7, 2022, with no new infections detected for the following 16 days, resulting in a period prevalence of 3.10 cases per 100,000 people. The demographic and clinical characteristics of the patients are summarized in Table 1 .

The median age of the 430 patients was 36 years (interquartile range [IQR],14-55), with 26.5% under 18. Female and male patients account for 55.6% and 44.4%, respectively. The most common onset symptoms were cough (37.0%) and fever (30.2%); parageusia (1.4%), heterosmia (0.9%), diarrhea (0.9%) and rash (0.2%) were rare (Table S1 ). 40.0% of the patients had at least one comorbidity, with hypertension (17.0%) and abnormal liver function (16.0%) being the most common (Table S2) . Patients with a history of SARS-COV-2 vaccination and child patients had fewer comorbidities as compared with vaccination-naïve patients (39.0% vs.

50.0%, P=0.001) and adult patients (3.5% vs. 53.2%, P<0.001), respectively.

Most patients presented with mild (47.7%) to moderate (50.2%) illness, with only 2 (0.5%) severe cases and no critical cases. A vast majority (82.5%) of the child patients had mild symptoms, with 12.3% moderate, 5.3% asymptomatic and no severe or critical cases. Adult patients were predominantly moderate cases (63.9%), followed by mild (35.1%), while severe and asymptomatic cases only accounted for 0.6% and 0.3%, respectively. Patients without comorbidities manifested less severe symptoms compared to those who had preexisting conditions at the time of Omicron infection (Table S3) . 4 .0% of the patients were admitted into ICU during hospitalization and were all adults.

Vaccinated patients showed a substantially lower risk of ICU admission as compared with those unvaccinated (2.0% vs. 23.7%, P<0.001). After turning negative on nucleic acid tests, a significantly higher proportion of unvaccinated patients experienced re-positive results than vaccinated patients (39.5% vs. 17.9%, P=0.001). The re-positive rate was lower for child patients than adult patients (12.3% vs. 22.5%, P=0.019). Patients demonstrating continuous clinical symptoms during recovery had higher re-positive rates than those without (33.3% vs. 16 .4%, P<0.001, Table S4 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ; 2 (0.5) 0 (0.0) 2 (0.6) 0 (0.0) * Percentages may not total 100 because of rounding. Continuous variables were shown in median (interquartile ranges) and categorical variables were summarized as counts (percentages). † Child was defined as younger than 18 years old. ‡ COVID-19 disease severity was defined according to WHO living guidance for clinical management of COVID-19. § PCR re-positive was defined as PCR Ct value less than 40 after two independent PCR-negative results with an interval of more than 24 hours.

Of the 430 patients infected with Omicron BA.1, 341 (79.3%) received inactivated vaccines (54.3% BBIBP-CorV, 45.5% CoronaVac and 0.3% other), 49 (11.4%) received adenovirusvectored vaccines (Ad5-nCoV), 2 (0.5%) recombinant protein subunit vaccine (ZF2001), and 38 (8.8%) were unvaccinated. The prevalence of infection among vaccinated individuals was 3.03/100,000, and 4.04/100,000 for the unvaccinated population (P=0.091). Given that Tianjin launched the vaccination programs for children aged between 3-11 years old since October 30, 2021, most of the infected children (82.5%) had received only 2 doses of inactivated vaccines, 3.5% received 1 dose, and 12.3% had received no vaccination.

Based on data from the 341 patients who had received inactivated vaccines and 38 patients who had no SARS-CoV-2 vaccination, we analyzed the correlation between the number of inactivated vaccine doses and disease severity ( Table 2 ). It was found that when all age groups are considered together, 2 doses of inactivated vaccines associate with a larger proportion of asymptomatic to mild disease (less severity) compared with 3 doses (P=0.003), which may be because most under-age patients had received 2 doses of inactivated vaccine and presented with mild illness. In adult patients, 3 doses reduced disease severity compared with no vaccination (P=0.004). ICU admission rate was only 0.6% for patients who had received a booster dose of inactivated vaccine and 4.8% for those who only received two-dose primary series, both significantly lower than the 27.5% for unvaccinated patients (P<0.001).

Receipt of two-dose primary series or three doses was associated with significantly lower rates of re-positive on nucleic acid tests. For patients across all age groups, the re-positive rate was 19.1% for those who had received 3 and 14.0% for those who had received 2 doses, both significantly lower than that of unvaccinated patients, which was 39.5% (P=0.008, P<0.001, respectively). For adult patients alone, receipt of 3 doses (19.4% vs. 50.0%, P=0.001) or 2 doses (19.0% vs. 50.0%, P=0.002) is also associated with lower re-positive rates than no vaccination.

The same relations were not statistically significant in child patients, due to the limited sample size.

Patients who had received a booster dose of inactivated vaccine experienced a shorter period of hospitalization and recovery. For patients across all age groups, the duration of hospitalization and recovery was 2 days shorter for those who had received 3 doses of 

(26-29) * Percentages may not total 100 because of rounding. Continuous variables were shown in median (interquartile ranges) and categorical variables were summarized as counts (percentages). † Child was defined as younger than 18 years old. ‡ COVID-19 disease severity was defined according to WHO living guidance for clinical management of COVID-19. § PCR re-positive was defined as PCR Ct value less than 40 after two independent PCR-negative results with an interval of more than 24 hours. & Duration was defined as the sum of the days of hospital stay and rehabilitation.

Vaccination status also correlated with immunity and inflammation-related laboratory findings (Table 3) . Compared with patients who had not been vaccinated against SARS-CoV-2, patients who had received 3 doses of inactivated vaccines showed significantly lower levels of the systemic immune-inflammatory index (SII) and C-reactive protein during the early stage of recovery after nucleic acid tests turned negative, suggesting that receipt of inactivated vaccine can step up inflammation resolution. Due to relatively lower levels of lymphocytes, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and monocyte/lymphocyte ratio (MLR) was higher in patients inoculated with three doses of inactivated vaccine than that of patients vaccinated with two doses. T cell clustering indicated that the booster dose of inactivated vaccine led to a significant elevation of the CD4+/CD8+ ratio, the ratio of activated Treg cells and the Th1/Th2 ratio. Tests of liver and kidney functions suggest that the number of inactivated vaccine doses did not affect liver and kidney function (Table S5) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ;  elevate plasma neutralizing titers, enabling a humoral immunity barrier against Omicron vairants.

Plasma neutralization against authentic SARS-CoV-2 wildtype strain, Beta strain, and Omicron strain is displayed. The geometric mean titer (GMT), geometric standard deviation, and fold-changes of 50% neutralization titers (NT50) are labeled. Dashed lines show the limit of detection. Statistical significance was determined by a two-tailed Wilcoxon test.

(a) NT50 from the breakthrough infection convalescents who were vaccinated with 2 (n=39) or 3 (n=80) doses of inactive vaccine.

(b) NT50 from the breakthrough infection convalescents who were vaccinated with BBIBP-CorV (n=54), CoronaVac (n=65) or Ad5-nCoV (n=16) vaccine.

(c) NT50 from the breakthrough infection convalescents with mild (n=36) or common (n=43) symptoms after 3 doses of inactive vaccine immunization.

(d) NT50 from the breakthrough infection convalescents who were vaccinated with 3 doses of CoronaVac vaccine (n=42) or from the uninfected vaccinees who were vaccinated with 3 doses of CoronaVac vaccine (n=114).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 Ordered multi-class logistic regression model was constructed based on age, gender and number of vaccine doses (Figure 2 ). In all age groups of patients, advanced age is a risk factor for severe disease (OR 1.063, 95% CI 1.048-1.078, P<0.001). Neither gender nor inactivated vaccine was significantly correlated with disease severity. Among adult patients, age is an adverse factor for severe disease (OR 1.044, 95% CI 1.024-1.064, P<0.001), while 3 doses of inactivated vaccine is a protective factor (OR 0.227, 95% CI 0.065-0.787, P=0.020). However, for child patients, no significant correlation was observed between age/gender/vaccination and disease severity. 

This has been the first study to report on the protective effect of inactivated vaccines against severe disease caused by the Omicron variant. Particularly, findings from this study suggest . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Previous studies reported a substantial decline of Omicron's replication ability in lung tissues, 7 and animal experiments found that viral RNA load is low in the lungs after infection, and no bronchitis or lung inflammation was observed. 8 Although the previous infection does confer protection against reinfection, such protective . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ;  https://doi.org/10.1101/2022.04.09.22273653 doi: medRxiv preprint effect is less pronounced in preventing reinfection by Omicron. 14 This is also reflected in the observation that the increase in neutralizing titer (against Omicron) is relatively mild after Omicron infection (compared to previous variants), which is probably due to the fact that Omicron is less effective at antagonizing the host cell interferon response, 15 19 Even when re-positive patients are defined by such standards, the re-positive rate among vaccinated patients remains low (Table S6) . No secondary infection was caused by the re-positive cases and no recurrence or worsening of symptoms was observed, which is a major difference from reinfection cases. This This study has several limitations. First, the sample of patients is small. Due to effective control efforts, the outbreak was soon contained and the number of cases was thus limited. We covered . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 

All authors declare no competing interests.

Although all data used in this analysis were anonymized, the individual level nature of the data used risks individuals being identified, or being able to self-identify, if the data are released publicly. Extracted data are available upon request. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022. ;  . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022. ;  . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.09.22273653 doi: medRxiv preprint Figure S1 . ICU admission according to subgroup in infected individuals by binary logistic regression. Figure S2 . PCR re-positive status according to subgroups in infected individuals by binary logistic regression. Figure S3 . Hospital stay and rehabilitation duration according to subgroup in infected individuals by binary logistic regression.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.09.22273653 doi: medRxiv preprint

World Health Organization. Tracking SARS-CoV-2 variants

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance

Tianjin Municipal Health Commission. Vaccination of COVID-19 in Tianjin

World Health Organization. Laboratory testing strategy recommendations for COVID-19: interim guidance

World Health Organization. Living guidance for clinical management of COVID-19: living guidance

SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire

Decoupling of omicron variant infections and severe COVID-19

Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? The Lancet Respiratory medicine 2021

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates

Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

COVID infection severity in children under 5 years old before and after Omicron emergence in the US

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections

Alkaline

 Table S5 . Correlation between hepatic and renal function and vaccination* * Data were missing for the measurement of glutamic pyruvic transaminase, glutamic oxalacetic transaminase, creatinine, urea nitrogen and UREA/CREA in 2 patients (0.5%), for total bilirubin, glutamyl transpeptidase, alkaline phosphatase and albumin in 322 patients (74.9%). Continuous variables were shown in median (interquartile ranges). † UREA/CREA was defined as the ratio of plasma urea nitrogen to plasma creatinine.